September 26, 2022 4:46pm

Moving into its electronic trading dynamics; buy/bid them up and then sell ‘em down

Pre-open indications: 2 HITs, 5 MISS and 1 Pump/Promote (BSTG, the usual suspect)

WHY and HOW is this market affecting the cell and gene therapy sector … “The Bottom Line” underlines the framework of share pricing actions.

Who else is tracking a broad grouping of cell and gene therapy equities – can you afford to not read facts supported by real numbers?

 

If I have learned one thing as a former research analyst in a venture and public fund now a journalist; it is that your life and your bank account are largely tied to your knowledge of price movements and questioning pricing targets.

 

The Dow closed DOWN -325.91 points (-1.10%) the S&P closed DOWN -37.76 points (-1.02%) while the Nasdaq closed DOWN -65 points (-0.60%)

 

Henry’omics:

Indexes waivered and then fell to the floorboards on Monday, with more volatility in store as fears of Fed tightening and wild run-in currency markets rattle investors.

The CBOE Volatility Index (VIX), which measures short-term market volatility, rose to 32.18 its highest level since June 17 and up from Friday’s 29.80.

 

Largest volume of multiple sessions:

  • bluebird bio (BLUE) 6.089 million shares (-$0.46) after Friday’s 5.87 M shares (-$0.35), Thursday’s 6.546 million shares (-$0.20), Wednesday’s +9.118 million shares traded (-$0.69), Tuesday’s +21.503 million shares traded (+$0.93) and last Monday’s -30.962 million share traded (-$0.41 or -6.47%) <average 3 mo. volume = 8.335 million shares>

 

RegMed Investor’s (RMi) Pre-Open: “what goes down for five (5) sector moves last week, needs some back-fill. However, it’s the last week of September which has been ugly for investors, could October be worse; also, Q3 closes.” … https://www.regmedinvestors.com/articles/12619

 

RegMed/Stem/Cell and Gene Therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what happened …

  • Monday’s advance/decline line opened positive at 27 up/ 7 down and 1 flat, flipped negative with 6 up/28 down and 1 flat at the mid-day, ending with a negative close of 5/30 and 0 flat.

 

Pre-open Indications: 2 HITs < BioLife Solutions (BLFS -$0.64), CRISPR Therapeutics (CRSP -$2.06)> 5 MISS <uniQure NV (QURE -$0.32), Intellia Therapeutics (NTLA +$0.28), Ultragenyx (RARE -$1.54), Agenus (AGEN -$0.17), Alnylam Pharmaceuticals (ALNY -$3.39)> 1 Pump/Promote < Biostage (OTCQB: BSTG +$0.39)>

 

Key Metrics:

  • Monday - Sector volume was LOW with 2 of the 5-upside having higher than the 3-month average volume with LOW volume of 2 of 30-downside having higher than the 3-month average volume

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Monday, the IBB was down -1.51% and the XBI was down -2.07%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Monday was up +2.26 points or +7.55% at 32.18

 

Jumping with share pricing momentum (5 of 5):

  • Biostage (OTCQB: BSTG +$0.39 after Friday’s -$1.39),
  • Intellia Therapeutics (NTLA +$0.28 after Friday’s -$3.16),
  • AxoGen (AXGN +$0.28),
  • Voyager Therapeutics (VYGR +$0.19),
  • Avrobio (AVRO +$0.0453),

Closing down (10 of 30):

  • Verve Therapeutics (VERV -$3.94 after Friday’s +$1.25),
  • Alnylam Pharmaceuticals (ALNY -$3.39 after Friday’s -$1.93),
  • CRISPR Therapeutics (CRSP -$2.05 after Friday’s -$1.74),
  • Ionis Pharmaceuticals (IONS -$1.48 after Friday’s -$1.74),
  • Vericel (VCEL -$1.04 after Friday’s +$0.21),
  • Fate Therapeutics (FATE -$0.93),
  • Sage Therapeutics (SAGE -$0.83 after Friday’s -$0.72),
  • BioLife Solutions (BLFS -$0.64),
  • Regenxbio (RGNX -$0.57),
  • Chinook Therapeutics (KDNY -$0.53 after Friday’s -$0.67),

 

September, Q3/202

  • Monday closed negative with 5 incliner, 30 decliners and 0 flat

 

The BOTTOM LINE: Cell and gene therapy equities ended the day in the RED – again, 6X in a row and running!

I try to keep it simple … and short!

Confidence is shaken while conviction is ruptured!

Which has added an enhanced volatility (a three-month high) to markets and reflexively the sector worried about recession amid decades-high inflation.

Hedge funds have partially thrown in the towel while most investors are stuck; it's also about uncertainty as Q3 ends this week and we’re back to LPS (loss-per-share) earnings reporting (Q3) season.

September continued with 1 holiday, 7 positive and 10 negative closes; August is over with 1 neutral, 11 positive and 11 negative closes while last week which ended the month.

As I continually question, “The real question that should be asked is how many companies are at the end of sentiments …  leash?

Start by looking at cell and gene therapy companies trading below cash!” 

I stick to my view of anticipating the risks – as my careers focus has been “warning analysis”.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.